Workflow
Alkermes(ALKS)
icon
Search documents
Alkermes(ALKS) - 2023 Q2 - Earnings Call Presentation
2023-07-26 21:06
Second Quarter 2023 Financial Results & Business Update July 26, 2023 ...
Alkermes(ALKS) - 2023 Q2 - Earnings Call Transcript
2023-07-26 16:12
Alkermes plc (NASDAQ:ALKS) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Corporate Affairs and Investor Relations Iain Brown – Chief Financial Officer Todd Nichols – Chief Commercial Officer Richard Pops – Chief Executive Officer Conference Call Participants Chris Shibutani – Goldman Sachs David Amsellem – Piper Sandler Paul Matteis – Stifel Umer Raffat – Evercore ISI Uy Ear – Mizuho Securities Marc Goodman – Leerink Partners Jason Gerbe ...
Alkermes(ALKS) - 2023 Q2 - Quarterly Report
2023-07-25 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 https://reportify- 1252068037.cos.ap- beijing.myqcloud.com/media/produ ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) ...
Alkermes(ALKS) - 2023 Q1 - Earnings Call Transcript
2023-04-26 21:05
Call Start: 08:00 January 1, 0000 9:01 AM ET Alkermes plc (NASDAQ:ALKS) Q1 2023 Earnings Conference Call April 26, 2023 08:00 ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations & Corporate Affairs Richard Pops - Chief Executive Officer Iain Brown - Chief Financial Officer Todd Nichols - Chief Commercial Officer Conference Call Participants Akash Tiwari - Jeffries Brandon Folkes - Cantor Fitzgerald Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs David Amsellem - Pi ...
Alkermes(ALKS) - 2023 Q1 - Quarterly Report
2023-04-25 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other jurisdiction of incorporation or o ...
Alkermes(ALKS) - 2022 Q4 - Earnings Call Presentation
2023-02-16 16:48
Fourth Quarter and Year-End 2022 Financial Results & Business Update February 16, 2023 © 2021 Alkermes. All rights reserved. © 2023 Alkermes. All rights reserved. Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations concerning ...
Alkermes(ALKS) - 2022 Q4 - Earnings Call Transcript
2023-02-16 16:46
Financial Data and Key Metrics Changes - The company reported total revenues of $1.11 billion for 2022, a 24% year-over-year growth driven primarily by proprietary products [17] - GAAP net loss for the year was $158.3 million, compared to a loss of $48.2 million in the prior year, while non-GAAP net income was $57.9 million, down from $129.1 million in 2021 [18] - The company ended 2022 with approximately $740 million in cash and total investments, and a positive net cash position of approximately $447 million [26] Business Line Data and Key Metrics Changes - LYBALVI generated net sales of $96 million in its first full year, with fourth-quarter sales of $34.9 million, up 29% sequentially [8][20] - ARISTADA net sales for the fourth quarter were $79.2 million, reflecting a 7% year-over-year growth [13] - VIVITROL achieved net sales of $379.5 million for 2022, up 10% year-over-year, with fourth-quarter sales of $102 million [14][18] Market Data and Key Metrics Changes - Total prescriptions for LYBALVI in the fourth quarter were approximately 28,400, representing a 23% growth quarter-over-quarter [9] - The prescriber base for LYBALVI increased by approximately 27% since the end of Q3, with about 7,600 prescribers having written prescriptions [9] - The company expects LYBALVI net sales in 2023 to range from $180 million to $205 million, while VIVITROL is expected to generate $380 million to $410 million [12][29] Company Strategy and Development Direction - The company plans to focus on three key areas in 2023: expanding prescriber breadth, enhancing patient access, and building awareness through direct-to-consumer advertising [11][35] - The planned separation of the oncology business is expected to enhance the financial profile of the neuroscience business, allowing for a clearer investment thesis [17][47] - The company aims to achieve long-term profitability targets, increasing non-GAAP net income margin targets to 25% in 2024 and 30% in 2025 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing launch of LYBALVI and its potential to drive significant revenue growth [36] - The company is optimistic about the orexin 2 receptor agonist program, with initial studies showing promising safety and tolerability profiles [38] - The separation of the oncology business is anticipated to unlock value and position both segments for growth [47] Other Important Information - The company recorded manufacturing and royalty revenues of $332 million for the year, down from $541.8 million in the prior year, primarily due to a decrease in royalties from long-acting INVEGA products [21][23] - Total operating expenses for 2022 were $1.25 billion, with R&D expenses reflecting focused investments in clinical programs [24][25] Q&A Session Summary Question: Can you discuss the balance between SG&A and R&D spend on the neuropsych business? - Management indicated that long-term margin targets depend on revenue growth and that investments in LYBALVI will continue to maximize opportunities [51] Question: On your long-term guide, how do you see LYBALVI's expectations evolving? - Management did not provide specific long-term expectations but emphasized that growth from proprietary products will drive profitability [55] Question: Can you clarify the dynamics of LYBALVI prescriptions? - Management noted that the growth in prescriptions is primarily driven by new prescribers, with a stable depth of prescribing [58] Question: What are the expectations for the orexin program's clinical trials? - Management confirmed that the current data is from single-ascending dose cohorts, with multiple ascending dose studies expected to start soon [61] Question: How will the oncology spin impact profitability targets? - The oncology spin is expected to reduce R&D costs significantly, aiding in achieving revised profitability targets [72]
Alkermes(ALKS) - 2022 Q4 - Annual Report
2023-02-15 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other juri ...
Alkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
2023-01-12 16:34
A Clear Investment Thesis Richard Pops Chief Executive Officer 41st Annual J.P. Morgan Healthcare Conference January 2023 © 2023 Alkermes. All rights reserved. Forward-Looking Statements Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations with respect to its current and future financial and operating per ...